Compare Amylx Pharmaceuticals Inc (AMLX) vs Keysight Technologies Inc (KEYS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Keysight Technologies Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Keysight Technologies Inc trades at $322.21 (market cap $55.04B). The key difference: Keysight Technologies Inc is far larger — about 27.8× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Keysight Technologies Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | KEYS | |
|---|---|---|
Market Cap | $1.98B | $55.04B |
Sector | Health | Technology |
52-Week High | $18.70 | $373.34 |
52-Week Low | $7.64 | $158.51 |
Enterprise Value | $1.70B | $55.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
KEYS trades at $322.05, down 0.04% on the day, with a bearish technical signal despite strong fundamentals. The company reported revenue of $5.38B in 2025 with net income of $850M, and has beaten EPS estimates for three consecutive quarters. Recent news highlights product launches in network cybersecurity and photonics design, supporting growth in AI and 5G markets.
Outlook remains positive with 75% analyst buy ratings and a $390.30 consensus price target, implying 21% upside. Key risks include high valuation multiples and volatile cash flows from significant investing activities. Earnings growth driven by technology demand presents the primary investment opportunity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →
